<DOC>
	<DOCNO>NCT00912535</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety quetiapine extend release tablet versus placebo adjunct selective serotonin reuptake inhibitors/serotonin/norepinephrine reuptake inhibitor ( SSRI/SNRI ) augmentation treatment patient primary anxiety disorder mood disorder co-morbid anxiety symptom .</brief_summary>
	<brief_title>Quetiapine Augmentation Primary Anxiety Disorder Mood Disorders With Co-morbid Anxiety Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision write informed consent A diagnosis primary anxiety disorder mood disorder comorbid anxiety symptom Diagnostic Statistical Manual Mental DisordersFourth Edition ( DSMIV ) A 14item Hamilton Anxiety Scale ( HAMA ) &gt; = 14 Subject receive single antidepressant therapeutic dose least 6 week Male female age 1865 year Female patient childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test enrollment Able understand comply requirement study sign inform consent Pregnancy lactation Any DSMIV Axis I disorder define inclusion criterion . Receiving antipsychotic 7 day prior enter study Patients , opinion investigator , post imminent risk suicide danger self others Known intolerance lack response quetiapine fumarate , judge investigator Use follow cytochrome P450 3A4 inhibitor 14 day precede enrollment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir Use follow cytochrome P450 3A4 inducer 14 day precede enrollment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St.John 's Wort , glucocorticoid Administration depot antipsychotic injection within one dose interval ( depot ) randomization Substance alcohol dependence enrollment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV criterion within 4 week prior enrollment Medical condition would affect absorption , distribution , metabolism , excretion study treatment Unstable inadequately treat medical illness ( e.g . congestive heart failure , angina pectoris , hypertension ) judge investigator Involvement planning conduct study Previous enrollment randomization treatment present study Participation another drug trial within 4 week prior enrollment study long accordance local requirement A patient Diabetes Mellitus ( DM ) fulfil one follow criterion : Unstable DM define enrollment glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % Admitted hospital treatment DM DM relate illness past 12 week . Not physician care DM Physician responsible patient 's DM care indicate patient 's DM control Physician responsible patient 's DM care approve patient 's participation study Has dose oral hypoglycaemic drug ( S ) and/or diet 4 week prior randomization . For thiazolidinediones ( glitazones ) period le 8 week Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week An absolute neutrophil count ( ANC ) &lt; = 1.5x10 ( 9 ) per liter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Primary Anxiety Disorders</keyword>
	<keyword>Mood Disorders Comorbid Anxiety Symptoms</keyword>
</DOC>